Head to Head Survey: Affymetrix (AFFX) and Veracyte (VCYT)
Affymetrix (NASDAQ: AFFX) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitabiliy, valuation and dividends.
Earnings and Valuation
This table compares Affymetrix and Veracyte’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Veracyte||$71.70 million||3.78||-$20.10 million||($0.80)||-10.00|
Affymetrix has higher revenue, but lower earnings than Veracyte.
This table compares Affymetrix and Veracyte’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and target prices for Affymetrix and Veracyte, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Veracyte has a consensus target price of $13.00, indicating a potential upside of 62.50%. Given Veracyte’s higher probable upside, analysts clearly believe Veracyte is more favorable than Affymetrix.
Institutional and Insider Ownership
63.4% of Veracyte shares are owned by institutional investors. 13.4% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Veracyte beats Affymetrix on 5 of the 8 factors compared between the two stocks.
Affymetrix, Inc. (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry. The eBioscience segment primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. It maintains sales and distribution operations across the United States, Europe, Latin America and Asia.
Veracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company’s commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.
Receive News & Ratings for Affymetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.